Diffuse endothelioma of bone, Proc NY Pathol Soc, vol.12, p.17, 1921. ,
Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies, Klin Pediatr, vol.211, pp.271-276, 1999. ,
Report from the Automated Childhood Cancer Information System project, Eur J Cancer, vol.42, pp.2124-2159, 1978. ,
Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma, Br J Cancer, vol.96, pp.1716-1738, 2007. ,
The neuroectodermal tumor of bone, Am J Surg Pathol, vol.8, pp.885-98, 1984. ,
Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics, Am J Surg Pathol, vol.25, pp.1061-1067, 2001. ,
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation, Proc Natl Acad Sci, vol.90, pp.5752-5758, 1993. ,
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein, J Biol Chem, vol.278, pp.15105-15120, 2003. ,
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression, Oncogene, vol.20, pp.3258-65, 2001. ,
Visual presentation of the staging of pediatric solid tumors, Radiographic, vol.16, pp.523-568, 1996. ,
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group, J Clin Oncol, vol.18, pp.3108-3122, 2000. ,
Death to the bad guys: targeting cancer via Apo2L/TRAIL, Apoptosis, vol.10, pp.35-51, 2005. ,
Role of osteoprotegerin (OPG) in cancer, Clin Sci (Lond), vol.110, pp.279-91, 2006. ,
Mechanisms of resistance to TRAIL-induced apoptosis in cancer, Cancer Gene Ther, vol.12, pp.228-265, 2005. ,
Monoclonal antibodies against TRAIL, Vitam Horm, vol.12, pp.65-79, 2004. ,
TRAIL and cancer therapy, Cancer Lett, vol.263, pp.14-25, 2008. ,
TRAIL as a target in anti-cancer therapy, Cancer Lett, vol.285, pp.1-5, 2009. ,
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1, J Clin Oncol, vol.25, pp.1390-1395, 2007. ,
an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study, J Clin Oncol, vol.27, pp.4413-4434, 2009. ,
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers, Clin Cancer Res, vol.13, pp.6187-94, 2007. ,
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors, Ann Oncol, vol.21, pp.376-81, 2010. ,
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5, Cell Death Differ, vol.15, pp.751-61, 2008. ,
Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis, Cell Death Differ, vol.8, pp.506-520, 2001. ,
Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2, Cancer Res, vol.61, pp.2704-2716, 2001. ,
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival, Clin Cancer Res, vol.16, pp.2363-74, 2010. ,
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4, Oncogene, vol.26, pp.3364-77, 2007. ,
TRAIL and apoptosis induction by TNF-family death receptors, Oncogene, vol.22, pp.8628-8661, 2003. ,
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICEinhibitory protein expression to TRAIL-induced apoptosis of melanoma, Cancer Res, vol.59, pp.2747-53, 1999. ,
Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J Gen Virol, vol.36, pp.59-74, 1977. ,
Mcl-1L cleavage is involved in TRAIL-R1-and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells, Blood, vol.108, pp.1346-52, 2006. ,
Breathnach R. Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown, J Immunol, vol.177, pp.6129-6165, 2006. ,
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5, Proc Natl Acad Sci, vol.100, pp.183-191, 2003. ,
Modularity in the TNF-receptor family, Trends Biochem Sci, vol.23, pp.74-83, 1998. ,
Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation, Nat Struct Mol Biol, vol.6, pp.1048-53, 1999. ,
Comparative protein modelling by satisfaction of spatial restraints, J Mol Biol, vol.234, pp.779-815, 1993. ,
Alternative splicing and programmed cell death, Proc Soc Exp Biol Med, vol.220, pp.64-72, 1999. ,
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL, Curr Biol, vol.7, pp.693-699, 1997. ,
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP, Mol Cancer Ther, vol.4, pp.2026-2062, 2005. ,
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death, Oncogene, vol.25, pp.838-886, 2006. ,
c-FLIP: a key regulator of colorectal cancer cell death, Cancer Res, vol.67, pp.5754-62, 2007. ,
Jalview Version 2-a multiple sequence alignment editor and analysis workbench, Mol Cancer Res Gaëlle Picarda, vol.25, pp.336-346, 2009. ,
New Short Isoform of Death Receptor 4 in Ewing's Updated version ,